Patent ID: 11931341
Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating muscular dystrophy or complications associated with muscular dystrophy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an AT2 receptor agonist or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein the muscular dystrophy is selected from the group consisting of Duchenne muscular dystrophy, myotonic dystrophy, facioscapulohumeral muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, oculopharyngeal muscular dystrophy, and Emery-Dreifuss muscular dystrophy, wherein the AT2 receptor agonist is N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21).